nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—VEGFA—uterine cancer	0.343	1	CbGaD
Vandetanib—ABCC1—Progesterone—uterine cancer	0.0561	0.201	CbGbCtD
Vandetanib—ABCC1—Dactinomycin—uterine cancer	0.0445	0.159	CbGbCtD
Vandetanib—ABCC1—Epirubicin—uterine cancer	0.0322	0.115	CbGbCtD
Vandetanib—ABCG2—Dactinomycin—uterine cancer	0.0298	0.106	CbGbCtD
Vandetanib—ABCC1—Etoposide—uterine cancer	0.0251	0.0898	CbGbCtD
Vandetanib—ABCG2—Carboplatin—uterine cancer	0.02	0.0716	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—uterine cancer	0.0171	0.0613	CbGbCtD
Vandetanib—ABCG2—Etoposide—uterine cancer	0.0168	0.0601	CbGbCtD
Vandetanib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0122	0.0438	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—uterine cancer	0.0115	0.041	CbGbCtD
Vandetanib—CYP3A4—Progesterone—uterine cancer	0.00811	0.029	CbGbCtD
Vandetanib—CYP3A4—Etoposide—uterine cancer	0.00363	0.013	CbGbCtD
Vandetanib—Afatinib—ERBB2—uterine cancer	0.00338	1	CrCbGaD
Vandetanib—CYP3A4—Doxorubicin—uterine cancer	0.00247	0.00886	CbGbCtD
Vandetanib—ERBB3—Podofilox—Etoposide—uterine cancer	0.000632	0.191	CbGdCrCtD
Vandetanib—VEGFA—uterine cervix—uterine cancer	0.000571	0.00516	CbGeAlD
Vandetanib—EPHB6—myometrium—uterine cancer	0.000568	0.00514	CbGeAlD
Vandetanib—FMO1—uterine cervix—uterine cancer	0.000568	0.00514	CbGeAlD
Vandetanib—IRAK4—uterine cervix—uterine cancer	0.000559	0.00506	CbGeAlD
Vandetanib—TYRO3—female reproductive system—uterine cancer	0.000558	0.00505	CbGeAlD
Vandetanib—VEGFA—smooth muscle tissue—uterine cancer	0.000555	0.00502	CbGeAlD
Vandetanib—ERBB3—epithelium—uterine cancer	0.000553	0.005	CbGeAlD
Vandetanib—YES1—myometrium—uterine cancer	0.000549	0.00497	CbGeAlD
Vandetanib—FLT4—decidua—uterine cancer	0.000548	0.00496	CbGeAlD
Vandetanib—ERBB3—uterine cervix—uterine cancer	0.000548	0.00495	CbGeAlD
Vandetanib—BMPR1B—female reproductive system—uterine cancer	0.000547	0.00495	CbGeAlD
Vandetanib—MAP3K19—female reproductive system—uterine cancer	0.000547	0.00495	CbGeAlD
Vandetanib—RIPK2—decidua—uterine cancer	0.000545	0.00493	CbGeAlD
Vandetanib—STK10—myometrium—uterine cancer	0.000544	0.00492	CbGeAlD
Vandetanib—VEGFA—decidua—uterine cancer	0.000544	0.00492	CbGeAlD
Vandetanib—IRAK4—decidua—uterine cancer	0.000533	0.00482	CbGeAlD
Vandetanib—FMO1—renal system—uterine cancer	0.000531	0.0048	CbGeAlD
Vandetanib—RIPK2—endometrium—uterine cancer	0.000518	0.00468	CbGeAlD
Vandetanib—EGFR—mammalian vulva—uterine cancer	0.000517	0.00467	CbGeAlD
Vandetanib—VEGFA—endometrium—uterine cancer	0.000516	0.00467	CbGeAlD
Vandetanib—MKNK1—uterine cervix—uterine cancer	0.000514	0.00465	CbGeAlD
Vandetanib—FMO1—endometrium—uterine cancer	0.000514	0.00464	CbGeAlD
Vandetanib—ERBB3—renal system—uterine cancer	0.000513	0.00464	CbGeAlD
Vandetanib—RET—epithelium—uterine cancer	0.000513	0.00463	CbGeAlD
Vandetanib—LCK—uterine cervix—uterine cancer	0.000508	0.0046	CbGeAlD
Vandetanib—TYRO3—female gonad—uterine cancer	0.000508	0.00459	CbGeAlD
Vandetanib—AXL—uterine cervix—uterine cancer	0.000506	0.00458	CbGeAlD
Vandetanib—IRAK4—endometrium—uterine cancer	0.000506	0.00457	CbGeAlD
Vandetanib—EPHA5—vagina—uterine cancer	0.000505	0.00457	CbGeAlD
Vandetanib—VEGFA—mammalian vulva—uterine cancer	0.000499	0.00452	CbGeAlD
Vandetanib—BMPR1B—female gonad—uterine cancer	0.000498	0.0045	CbGeAlD
Vandetanib—FMO1—mammalian vulva—uterine cancer	0.000497	0.00449	CbGeAlD
Vandetanib—EGFR—uterus—uterine cancer	0.000492	0.00445	CbGeAlD
Vandetanib—AXL—smooth muscle tissue—uterine cancer	0.000492	0.00445	CbGeAlD
Vandetanib—MKNK1—decidua—uterine cancer	0.00049	0.00443	CbGeAlD
Vandetanib—IRAK4—mammalian vulva—uterine cancer	0.000489	0.00442	CbGeAlD
Vandetanib—SLK—uterine cervix—uterine cancer	0.000487	0.00441	CbGeAlD
Vandetanib—MAP2K5—myometrium—uterine cancer	0.000486	0.0044	CbGeAlD
Vandetanib—KDR—myometrium—uterine cancer	0.000486	0.0044	CbGeAlD
Vandetanib—PLK4—Teniposide—Etoposide—uterine cancer	0.000484	0.146	CbGdCrCtD
Vandetanib—LCK—decidua—uterine cancer	0.000484	0.00438	CbGeAlD
Vandetanib—FGR—decidua—uterine cancer	0.000484	0.00438	CbGeAlD
Vandetanib—RET—decidua—uterine cancer	0.000484	0.00438	CbGeAlD
Vandetanib—AXL—decidua—uterine cancer	0.000482	0.00436	CbGeAlD
Vandetanib—VEGFA—uterus—uterine cancer	0.000476	0.0043	CbGeAlD
Vandetanib—RET—renal system—uterine cancer	0.000475	0.0043	CbGeAlD
Vandetanib—FLT3—female reproductive system—uterine cancer	0.000475	0.00429	CbGeAlD
Vandetanib—FYN—uterine cervix—uterine cancer	0.000474	0.00428	CbGeAlD
Vandetanib—TEK—epithelium—uterine cancer	0.000467	0.00422	CbGeAlD
Vandetanib—MKNK1—endometrium—uterine cancer	0.000465	0.00421	CbGeAlD
Vandetanib—STK35—female reproductive system—uterine cancer	0.000465	0.00421	CbGeAlD
Vandetanib—SLK—decidua—uterine cancer	0.000464	0.0042	CbGeAlD
Vandetanib—MAP4K5—uterine cervix—uterine cancer	0.000463	0.00419	CbGeAlD
Vandetanib—FYN—smooth muscle tissue—uterine cancer	0.00046	0.00416	CbGeAlD
Vandetanib—FGR—endometrium—uterine cancer	0.00046	0.00416	CbGeAlD
Vandetanib—AXL—endometrium—uterine cancer	0.000458	0.00414	CbGeAlD
Vandetanib—ERBB3—uterus—uterine cancer	0.000457	0.00413	CbGeAlD
Vandetanib—FYN—decidua—uterine cancer	0.000451	0.00408	CbGeAlD
Vandetanib—MKNK1—mammalian vulva—uterine cancer	0.00045	0.00407	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—uterine cancer	0.00045	0.00407	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—uterine cancer	0.00045	0.00407	CbGeAlD
Vandetanib—BLK—lymph node—uterine cancer	0.000445	0.00403	CbGeAlD
Vandetanib—LCK—mammalian vulva—uterine cancer	0.000445	0.00402	CbGeAlD
Vandetanib—FGR—mammalian vulva—uterine cancer	0.000445	0.00402	CbGeAlD
Vandetanib—FYN—renal system—uterine cancer	0.000443	0.00401	CbGeAlD
Vandetanib—AXL—mammalian vulva—uterine cancer	0.000443	0.004	CbGeAlD
Vandetanib—EPHB6—uterine cervix—uterine cancer	0.000442	0.004	CbGeAlD
Vandetanib—TEK—decidua—uterine cancer	0.000441	0.00399	CbGeAlD
Vandetanib—MAP4K5—decidua—uterine cancer	0.000441	0.00399	CbGeAlD
Vandetanib—SLK—endometrium—uterine cancer	0.000441	0.00398	CbGeAlD
Vandetanib—LTK—lymph node—uterine cancer	0.00044	0.00398	CbGeAlD
Vandetanib—TEK—renal system—uterine cancer	0.000433	0.00392	CbGeAlD
Vandetanib—FLT3—female gonad—uterine cancer	0.000432	0.00391	CbGeAlD
Vandetanib—FLT4—female reproductive system—uterine cancer	0.000431	0.0039	CbGeAlD
Vandetanib—FMO3—mammalian vulva—uterine cancer	0.000429	0.00388	CbGeAlD
Vandetanib—RIPK2—female reproductive system—uterine cancer	0.000429	0.00388	CbGeAlD
Vandetanib—FYN—endometrium—uterine cancer	0.000428	0.00387	CbGeAlD
Vandetanib—YES1—uterine cervix—uterine cancer	0.000428	0.00387	CbGeAlD
Vandetanib—SLK—mammalian vulva—uterine cancer	0.000426	0.00385	CbGeAlD
Vandetanib—STK10—uterine cervix—uterine cancer	0.000424	0.00383	CbGeAlD
Vandetanib—LCK—uterus—uterine cancer	0.000424	0.00383	CbGeAlD
Vandetanib—STK35—female gonad—uterine cancer	0.000423	0.00383	CbGeAlD
Vandetanib—AXL—uterus—uterine cancer	0.000422	0.00381	CbGeAlD
Vandetanib—EPHB6—decidua—uterine cancer	0.000421	0.00381	CbGeAlD
Vandetanib—PDGFRB—myometrium—uterine cancer	0.000421	0.00381	CbGeAlD
Vandetanib—STK35—vagina—uterine cancer	0.000421	0.0038	CbGeAlD
Vandetanib—MAP4K5—endometrium—uterine cancer	0.000419	0.00379	CbGeAlD
Vandetanib—TEK—endometrium—uterine cancer	0.000419	0.00379	CbGeAlD
Vandetanib—YES1—smooth muscle tissue—uterine cancer	0.000415	0.00376	CbGeAlD
Vandetanib—SRC—epithelium—uterine cancer	0.000415	0.00375	CbGeAlD
Vandetanib—FYN—mammalian vulva—uterine cancer	0.000414	0.00375	CbGeAlD
Vandetanib—ABL2—female gonad—uterine cancer	0.000412	0.00373	CbGeAlD
Vandetanib—SRC—uterine cervix—uterine cancer	0.000411	0.00372	CbGeAlD
Vandetanib—ERBB3—female reproductive system—uterine cancer	0.000411	0.00371	CbGeAlD
Vandetanib—ABL2—vagina—uterine cancer	0.00041	0.00371	CbGeAlD
Vandetanib—YES1—decidua—uterine cancer	0.000407	0.00368	CbGeAlD
Vandetanib—SLK—uterus—uterine cancer	0.000406	0.00367	CbGeAlD
Vandetanib—MAP4K5—mammalian vulva—uterine cancer	0.000405	0.00366	CbGeAlD
Vandetanib—STK10—decidua—uterine cancer	0.000404	0.00365	CbGeAlD
Vandetanib—EGFR—female gonad—uterine cancer	0.000403	0.00364	CbGeAlD
Vandetanib—EPHB6—endometrium—uterine cancer	0.0004	0.00362	CbGeAlD
Vandetanib—YES1—renal system—uterine cancer	0.0004	0.00362	CbGeAlD
Vandetanib—SRC—smooth muscle tissue—uterine cancer	0.0004	0.00361	CbGeAlD
Vandetanib—STK10—renal system—uterine cancer	0.000396	0.00358	CbGeAlD
Vandetanib—FYN—uterus—uterine cancer	0.000395	0.00357	CbGeAlD
Vandetanib—FLT4—female gonad—uterine cancer	0.000392	0.00355	CbGeAlD
Vandetanib—SRC—decidua—uterine cancer	0.000392	0.00354	CbGeAlD
Vandetanib—RIPK2—female gonad—uterine cancer	0.00039	0.00353	CbGeAlD
Vandetanib—VEGFA—female gonad—uterine cancer	0.000389	0.00352	CbGeAlD
Vandetanib—RIPK2—vagina—uterine cancer	0.000388	0.00351	CbGeAlD
Vandetanib—FMO1—female gonad—uterine cancer	0.000387	0.0035	CbGeAlD
Vandetanib—EPHB6—mammalian vulva—uterine cancer	0.000387	0.0035	CbGeAlD
Vandetanib—VEGFA—vagina—uterine cancer	0.000387	0.0035	CbGeAlD
Vandetanib—YES1—endometrium—uterine cancer	0.000387	0.0035	CbGeAlD
Vandetanib—TEK—uterus—uterine cancer	0.000386	0.00349	CbGeAlD
Vandetanib—MAP4K5—uterus—uterine cancer	0.000386	0.00349	CbGeAlD
Vandetanib—MKNK1—female reproductive system—uterine cancer	0.000385	0.00349	CbGeAlD
Vandetanib—FMO1—vagina—uterine cancer	0.000385	0.00348	CbGeAlD
Vandetanib—SRC—renal system—uterine cancer	0.000385	0.00348	CbGeAlD
Vandetanib—KDR—epithelium—uterine cancer	0.000382	0.00345	CbGeAlD
Vandetanib—IRAK4—female gonad—uterine cancer	0.000381	0.00345	CbGeAlD
Vandetanib—FGR—female reproductive system—uterine cancer	0.000381	0.00344	CbGeAlD
Vandetanib—AXL—female reproductive system—uterine cancer	0.000379	0.00343	CbGeAlD
Vandetanib—IRAK4—vagina—uterine cancer	0.000379	0.00343	CbGeAlD
Vandetanib—MAP2K5—uterine cervix—uterine cancer	0.000378	0.00342	CbGeAlD
Vandetanib—KDR—uterine cervix—uterine cancer	0.000378	0.00342	CbGeAlD
Vandetanib—ABL1—myometrium—uterine cancer	0.000375	0.00339	CbGeAlD
Vandetanib—YES1—mammalian vulva—uterine cancer	0.000374	0.00338	CbGeAlD
Vandetanib—ERBB3—female gonad—uterine cancer	0.000374	0.00338	CbGeAlD
Vandetanib—STK10—mammalian vulva—uterine cancer	0.000371	0.00335	CbGeAlD
Vandetanib—KDR—smooth muscle tissue—uterine cancer	0.000368	0.00332	CbGeAlD
Vandetanib—KDR—decidua—uterine cancer	0.00036	0.00326	CbGeAlD
Vandetanib—MAP2K5—decidua—uterine cancer	0.00036	0.00326	CbGeAlD
Vandetanib—YES1—uterus—uterine cancer	0.000356	0.00322	CbGeAlD
Vandetanib—FYN—female reproductive system—uterine cancer	0.000355	0.00321	CbGeAlD
Vandetanib—KDR—renal system—uterine cancer	0.000354	0.0032	CbGeAlD
Vandetanib—STK10—uterus—uterine cancer	0.000353	0.00319	CbGeAlD
Vandetanib—MKNK1—female gonad—uterine cancer	0.000351	0.00317	CbGeAlD
Vandetanib—MKNK1—vagina—uterine cancer	0.000349	0.00315	CbGeAlD
Vandetanib—PLK4—lymph node—uterine cancer	0.000348	0.00314	CbGeAlD
Vandetanib—MAP4K5—female reproductive system—uterine cancer	0.000347	0.00314	CbGeAlD
Vandetanib—TEK—female reproductive system—uterine cancer	0.000347	0.00314	CbGeAlD
Vandetanib—FGR—female gonad—uterine cancer	0.000346	0.00313	CbGeAlD
Vandetanib—LCK—female gonad—uterine cancer	0.000346	0.00313	CbGeAlD
Vandetanib—AXL—female gonad—uterine cancer	0.000345	0.00312	CbGeAlD
Vandetanib—LCK—vagina—uterine cancer	0.000344	0.00311	CbGeAlD
Vandetanib—FGR—vagina—uterine cancer	0.000344	0.00311	CbGeAlD
Vandetanib—AXL—vagina—uterine cancer	0.000343	0.0031	CbGeAlD
Vandetanib—KDR—endometrium—uterine cancer	0.000342	0.00309	CbGeAlD
Vandetanib—MAP2K5—endometrium—uterine cancer	0.000342	0.00309	CbGeAlD
Vandetanib—FMO3—vagina—uterine cancer	0.000333	0.00301	CbGeAlD
Vandetanib—SLK—female gonad—uterine cancer	0.000332	0.003	CbGeAlD
Vandetanib—MAP2K5—mammalian vulva—uterine cancer	0.000331	0.00299	CbGeAlD
Vandetanib—KDR—mammalian vulva—uterine cancer	0.000331	0.00299	CbGeAlD
Vandetanib—PDGFRB—epithelium—uterine cancer	0.00033	0.00299	CbGeAlD
Vandetanib—SLK—vagina—uterine cancer	0.00033	0.00299	CbGeAlD
Vandetanib—PDGFRB—uterine cervix—uterine cancer	0.000327	0.00296	CbGeAlD
Vandetanib—FYN—female gonad—uterine cancer	0.000323	0.00292	CbGeAlD
Vandetanib—FYN—vagina—uterine cancer	0.000321	0.0029	CbGeAlD
Vandetanib—YES1—female reproductive system—uterine cancer	0.00032	0.0029	CbGeAlD
Vandetanib—BMPR1B—lymph node—uterine cancer	0.00032	0.00289	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—uterine cancer	0.000318	0.00288	CbGeAlD
Vandetanib—STK10—female reproductive system—uterine cancer	0.000317	0.00287	CbGeAlD
Vandetanib—MAP4K5—female gonad—uterine cancer	0.000316	0.00285	CbGeAlD
Vandetanib—TEK—female gonad—uterine cancer	0.000316	0.00285	CbGeAlD
Vandetanib—KDR—uterus—uterine cancer	0.000315	0.00285	CbGeAlD
Vandetanib—MAP4K5—vagina—uterine cancer	0.000314	0.00284	CbGeAlD
Vandetanib—PDGFRB—decidua—uterine cancer	0.000312	0.00282	CbGeAlD
Vandetanib—SRC—female reproductive system—uterine cancer	0.000308	0.00279	CbGeAlD
Vandetanib—PDGFRB—renal system—uterine cancer	0.000306	0.00277	CbGeAlD
Vandetanib—EPHB6—female gonad—uterine cancer	0.000302	0.00273	CbGeAlD
Vandetanib—EPHB6—vagina—uterine cancer	0.0003	0.00271	CbGeAlD
Vandetanib—PDGFRB—endometrium—uterine cancer	0.000296	0.00268	CbGeAlD
Vandetanib—ABL1—uterine cervix—uterine cancer	0.000292	0.00264	CbGeAlD
Vandetanib—YES1—female gonad—uterine cancer	0.000291	0.00264	CbGeAlD
Vandetanib—YES1—vagina—uterine cancer	0.00029	0.00262	CbGeAlD
Vandetanib—STK10—female gonad—uterine cancer	0.000289	0.00261	CbGeAlD
Vandetanib—STK10—vagina—uterine cancer	0.000287	0.0026	CbGeAlD
Vandetanib—PDGFRB—mammalian vulva—uterine cancer	0.000286	0.00259	CbGeAlD
Vandetanib—ABCC1—myometrium—uterine cancer	0.000286	0.00258	CbGeAlD
Vandetanib—ABL1—smooth muscle tissue—uterine cancer	0.000284	0.00257	CbGeAlD
Vandetanib—MAP2K5—female reproductive system—uterine cancer	0.000283	0.00256	CbGeAlD
Vandetanib—KDR—female reproductive system—uterine cancer	0.000283	0.00256	CbGeAlD
Vandetanib—SRC—female gonad—uterine cancer	0.00028	0.00254	CbGeAlD
Vandetanib—ABL1—decidua—uterine cancer	0.000278	0.00251	CbGeAlD
Vandetanib—ORM1—endometrium—uterine cancer	0.000278	0.00251	CbGeAlD
Vandetanib—FLT3—lymph node—uterine cancer	0.000278	0.00251	CbGeAlD
Vandetanib—ABL1—renal system—uterine cancer	0.000273	0.00247	CbGeAlD
Vandetanib—PDGFRB—uterus—uterine cancer	0.000273	0.00247	CbGeAlD
Vandetanib—STK35—lymph node—uterine cancer	0.000272	0.00246	CbGeAlD
Vandetanib—ABL2—lymph node—uterine cancer	0.000265	0.0024	CbGeAlD
Vandetanib—ABL1—endometrium—uterine cancer	0.000264	0.00239	CbGeAlD
Vandetanib—EGFR—lymph node—uterine cancer	0.000259	0.00234	CbGeAlD
Vandetanib—KDR—female gonad—uterine cancer	0.000258	0.00233	CbGeAlD
Vandetanib—MAP2K5—female gonad—uterine cancer	0.000258	0.00233	CbGeAlD
Vandetanib—KDR—vagina—uterine cancer	0.000256	0.00232	CbGeAlD
Vandetanib—MAP2K5—vagina—uterine cancer	0.000256	0.00232	CbGeAlD
Vandetanib—ABL1—mammalian vulva—uterine cancer	0.000255	0.00231	CbGeAlD
Vandetanib—PLK4—Doxorubicin—Epirubicin—uterine cancer	0.000253	0.0762	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Epirubicin—uterine cancer	0.000253	0.0762	CbGdCrCtD
Vandetanib—FLT4—lymph node—uterine cancer	0.000252	0.00228	CbGeAlD
Vandetanib—RIPK2—lymph node—uterine cancer	0.000251	0.00227	CbGeAlD
Vandetanib—VEGFA—lymph node—uterine cancer	0.00025	0.00226	CbGeAlD
Vandetanib—FMO1—lymph node—uterine cancer	0.000249	0.00225	CbGeAlD
Vandetanib—PDGFRB—female reproductive system—uterine cancer	0.000245	0.00222	CbGeAlD
Vandetanib—IRAK4—lymph node—uterine cancer	0.000245	0.00222	CbGeAlD
Vandetanib—ABL1—uterus—uterine cancer	0.000243	0.0022	CbGeAlD
Vandetanib—ERBB3—lymph node—uterine cancer	0.00024	0.00217	CbGeAlD
Vandetanib—ABCG2—myometrium—uterine cancer	0.000237	0.00214	CbGeAlD
Vandetanib—PLK4—Idarubicin—Doxorubicin—uterine cancer	0.000234	0.0705	CbGdCrCtD
Vandetanib—PLK4—Epirubicin—Doxorubicin—uterine cancer	0.000234	0.0705	CbGdCrCtD
Vandetanib—ORM1—female reproductive system—uterine cancer	0.00023	0.00208	CbGeAlD
Vandetanib—MKNK1—lymph node—uterine cancer	0.000225	0.00204	CbGeAlD
Vandetanib—PDGFRB—female gonad—uterine cancer	0.000223	0.00202	CbGeAlD
Vandetanib—FGR—lymph node—uterine cancer	0.000223	0.00201	CbGeAlD
Vandetanib—RET—lymph node—uterine cancer	0.000223	0.00201	CbGeAlD
Vandetanib—LCK—lymph node—uterine cancer	0.000223	0.00201	CbGeAlD
Vandetanib—ABCC1—uterine cervix—uterine cancer	0.000222	0.00201	CbGeAlD
Vandetanib—PDGFRB—vagina—uterine cancer	0.000222	0.00201	CbGeAlD
Vandetanib—AXL—lymph node—uterine cancer	0.000222	0.00201	CbGeAlD
Vandetanib—ABL1—female reproductive system—uterine cancer	0.000219	0.00198	CbGeAlD
Vandetanib—FMO3—lymph node—uterine cancer	0.000215	0.00195	CbGeAlD
Vandetanib—SLK—lymph node—uterine cancer	0.000214	0.00193	CbGeAlD
Vandetanib—ABL1—Doxorubicin—Epirubicin—uterine cancer	0.000212	0.064	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Epirubicin—uterine cancer	0.000212	0.064	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—uterine cancer	0.000212	0.064	CbGdCrCtD
Vandetanib—ABCC1—decidua—uterine cancer	0.000212	0.00192	CbGeAlD
Vandetanib—FYN—lymph node—uterine cancer	0.000208	0.00188	CbGeAlD
Vandetanib—MAP4K5—lymph node—uterine cancer	0.000203	0.00183	CbGeAlD
Vandetanib—TEK—lymph node—uterine cancer	0.000203	0.00183	CbGeAlD
Vandetanib—ABCC1—endometrium—uterine cancer	0.000201	0.00182	CbGeAlD
Vandetanib—ABL1—female gonad—uterine cancer	0.000199	0.0018	CbGeAlD
Vandetanib—ABL1—vagina—uterine cancer	0.000198	0.00179	CbGeAlD
Vandetanib—ABL1—Epirubicin—Doxorubicin—uterine cancer	0.000197	0.0593	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—uterine cancer	0.000197	0.0593	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—uterine cancer	0.000197	0.0593	CbGdCrCtD
Vandetanib—ABCC1—mammalian vulva—uterine cancer	0.000195	0.00176	CbGeAlD
Vandetanib—EPHB6—lymph node—uterine cancer	0.000194	0.00175	CbGeAlD
Vandetanib—YES1—lymph node—uterine cancer	0.000187	0.00169	CbGeAlD
Vandetanib—STK10—lymph node—uterine cancer	0.000186	0.00168	CbGeAlD
Vandetanib—ABCC1—uterus—uterine cancer	0.000185	0.00168	CbGeAlD
Vandetanib—ABCG2—uterine cervix—uterine cancer	0.000184	0.00166	CbGeAlD
Vandetanib—SRC—lymph node—uterine cancer	0.00018	0.00163	CbGeAlD
Vandetanib—ABCG2—decidua—uterine cancer	0.000175	0.00159	CbGeAlD
Vandetanib—ABCG2—endometrium—uterine cancer	0.000166	0.00151	CbGeAlD
Vandetanib—KDR—lymph node—uterine cancer	0.000166	0.0015	CbGeAlD
Vandetanib—MAP2K5—lymph node—uterine cancer	0.000166	0.0015	CbGeAlD
Vandetanib—ABCG2—mammalian vulva—uterine cancer	0.000161	0.00146	CbGeAlD
Vandetanib—ABCG2—uterus—uterine cancer	0.000153	0.00139	CbGeAlD
Vandetanib—Dry eye—Doxorubicin—uterine cancer	0.000153	0.0013	CcSEcCtD
Vandetanib—Diarrhoea—Progesterone—uterine cancer	0.000152	0.0013	CcSEcCtD
Vandetanib—ABCC1—female gonad—uterine cancer	0.000152	0.00137	CbGeAlD
Vandetanib—Erythema multiforme—Etoposide—uterine cancer	0.000151	0.00129	CcSEcCtD
Vandetanib—ABCC1—vagina—uterine cancer	0.000151	0.00136	CbGeAlD
Vandetanib—Eye disorder—Etoposide—uterine cancer	0.000149	0.00128	CcSEcCtD
Vandetanib—Bladder pain—Doxorubicin—uterine cancer	0.000149	0.00127	CcSEcCtD
Vandetanib—Neoplasm—Doxorubicin—uterine cancer	0.000149	0.00127	CcSEcCtD
Vandetanib—Cardiac disorder—Etoposide—uterine cancer	0.000148	0.00127	CcSEcCtD
Vandetanib—Dizziness—Progesterone—uterine cancer	0.000147	0.00125	CcSEcCtD
Vandetanib—Angiopathy—Etoposide—uterine cancer	0.000145	0.00124	CcSEcCtD
Vandetanib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000144	0.00123	CcSEcCtD
Vandetanib—Mediastinal disorder—Etoposide—uterine cancer	0.000144	0.00123	CcSEcCtD
Vandetanib—PDGFRB—lymph node—uterine cancer	0.000144	0.0013	CbGeAlD
Vandetanib—Sepsis—Doxorubicin—uterine cancer	0.000143	0.00122	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000143	0.00122	CcSEcCtD
Vandetanib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000142	0.00122	CcSEcCtD
Vandetanib—Alopecia—Etoposide—uterine cancer	0.000141	0.00121	CcSEcCtD
Vandetanib—Vomiting—Progesterone—uterine cancer	0.000141	0.00121	CcSEcCtD
Vandetanib—Rash—Progesterone—uterine cancer	0.00014	0.0012	CcSEcCtD
Vandetanib—Dermatitis—Progesterone—uterine cancer	0.00014	0.00119	CcSEcCtD
Vandetanib—Headache—Progesterone—uterine cancer	0.000139	0.00119	CcSEcCtD
Vandetanib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000138	0.00118	CcSEcCtD
Vandetanib—Decreased appetite—Dactinomycin—uterine cancer	0.000136	0.00116	CcSEcCtD
Vandetanib—Dysgeusia—Etoposide—uterine cancer	0.000136	0.00116	CcSEcCtD
Vandetanib—Dermatitis bullous—Epirubicin—uterine cancer	0.000136	0.00116	CcSEcCtD
Vandetanib—Fatigue—Dactinomycin—uterine cancer	0.000135	0.00115	CcSEcCtD
Vandetanib—ORM1—lymph node—uterine cancer	0.000135	0.00122	CbGeAlD
Vandetanib—Pain—Dactinomycin—uterine cancer	0.000134	0.00115	CcSEcCtD
Vandetanib—Muscle spasms—Etoposide—uterine cancer	0.000134	0.00114	CcSEcCtD
Vandetanib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000133	0.00114	CcSEcCtD
Vandetanib—Hypoglycaemia—Epirubicin—uterine cancer	0.000133	0.00113	CcSEcCtD
Vandetanib—Cardiac failure—Epirubicin—uterine cancer	0.000133	0.00113	CcSEcCtD
Vandetanib—Lethargy—Epirubicin—uterine cancer	0.000132	0.00113	CcSEcCtD
Vandetanib—Nausea—Progesterone—uterine cancer	0.000132	0.00113	CcSEcCtD
Vandetanib—Hyponatraemia—Epirubicin—uterine cancer	0.00013	0.00111	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.00013	0.00111	CcSEcCtD
Vandetanib—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000128	0.0011	CcSEcCtD
Vandetanib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000128	0.00109	CcSEcCtD
Vandetanib—ABL1—lymph node—uterine cancer	0.000128	0.00116	CbGeAlD
Vandetanib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000127	0.00108	CcSEcCtD
Vandetanib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000127	0.00108	CcSEcCtD
Vandetanib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000126	0.00108	CcSEcCtD
Vandetanib—ABCG2—female gonad—uterine cancer	0.000125	0.00113	CbGeAlD
Vandetanib—Dermatitis bullous—Doxorubicin—uterine cancer	0.000125	0.00107	CcSEcCtD
Vandetanib—ABCG2—vagina—uterine cancer	0.000125	0.00113	CbGeAlD
Vandetanib—Body temperature increased—Dactinomycin—uterine cancer	0.000124	0.00106	CcSEcCtD
Vandetanib—Abdominal pain—Dactinomycin—uterine cancer	0.000124	0.00106	CcSEcCtD
Vandetanib—Cardiac arrest—Epirubicin—uterine cancer	0.000123	0.00105	CcSEcCtD
Vandetanib—Hypoglycaemia—Doxorubicin—uterine cancer	0.000123	0.00105	CcSEcCtD
Vandetanib—Cardiac failure—Doxorubicin—uterine cancer	0.000123	0.00105	CcSEcCtD
Vandetanib—Loss of consciousness—Etoposide—uterine cancer	0.000122	0.00104	CcSEcCtD
Vandetanib—Lethargy—Doxorubicin—uterine cancer	0.000122	0.00104	CcSEcCtD
Vandetanib—Cough—Etoposide—uterine cancer	0.000122	0.00104	CcSEcCtD
Vandetanib—Blood creatinine increased—Epirubicin—uterine cancer	0.000121	0.00104	CcSEcCtD
Vandetanib—Convulsion—Etoposide—uterine cancer	0.000121	0.00103	CcSEcCtD
Vandetanib—Dehydration—Epirubicin—uterine cancer	0.000121	0.00103	CcSEcCtD
Vandetanib—Hyponatraemia—Doxorubicin—uterine cancer	0.00012	0.00103	CcSEcCtD
Vandetanib—Hypertension—Etoposide—uterine cancer	0.00012	0.00103	CcSEcCtD
Vandetanib—CYP3A4—renal system—uterine cancer	0.00012	0.00108	CbGeAlD
Vandetanib—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.00012	0.00102	CcSEcCtD
Vandetanib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00012	0.00102	CcSEcCtD
Vandetanib—Dry skin—Epirubicin—uterine cancer	0.000119	0.00101	CcSEcCtD
Vandetanib—Chest pain—Etoposide—uterine cancer	0.000119	0.00101	CcSEcCtD
Vandetanib—ALB—lymph node—uterine cancer	0.000118	0.00107	CbGeAlD
Vandetanib—Hypokalaemia—Epirubicin—uterine cancer	0.000118	0.00101	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000118	0.001	CcSEcCtD
Vandetanib—Nasopharyngitis—Epirubicin—uterine cancer	0.000116	0.000989	CcSEcCtD
Vandetanib—Gastritis—Epirubicin—uterine cancer	0.000115	0.000979	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000114	0.000975	CcSEcCtD
Vandetanib—Cardiac arrest—Doxorubicin—uterine cancer	0.000114	0.000973	CcSEcCtD
Vandetanib—Infection—Etoposide—uterine cancer	0.000113	0.000963	CcSEcCtD
Vandetanib—Asthenia—Dactinomycin—uterine cancer	0.000113	0.000961	CcSEcCtD
Vandetanib—Blood creatinine increased—Doxorubicin—uterine cancer	0.000112	0.000959	CcSEcCtD
Vandetanib—Dysphagia—Epirubicin—uterine cancer	0.000112	0.000956	CcSEcCtD
Vandetanib—Influenza—Epirubicin—uterine cancer	0.000112	0.000956	CcSEcCtD
Vandetanib—Dehydration—Doxorubicin—uterine cancer	0.000112	0.000952	CcSEcCtD
Vandetanib—Thrombocytopenia—Etoposide—uterine cancer	0.000111	0.000949	CcSEcCtD
Vandetanib—Skin disorder—Etoposide—uterine cancer	0.00011	0.000942	CcSEcCtD
Vandetanib—Dry skin—Doxorubicin—uterine cancer	0.00011	0.000938	CcSEcCtD
Vandetanib—Pancreatitis—Epirubicin—uterine cancer	0.00011	0.000937	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—uterine cancer	0.000109	0.000931	CcSEcCtD
Vandetanib—Bronchitis—Epirubicin—uterine cancer	0.000108	0.000919	CcSEcCtD
Vandetanib—Diarrhoea—Dactinomycin—uterine cancer	0.000107	0.000917	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—uterine cancer	0.000107	0.000915	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—uterine cancer	0.000106	0.000905	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000106	0.000902	CcSEcCtD
Vandetanib—Neutropenia—Epirubicin—uterine cancer	0.000105	0.000894	CcSEcCtD
Vandetanib—Dysuria—Epirubicin—uterine cancer	0.000105	0.000894	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000104	0.000888	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—uterine cancer	0.000104	0.000884	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—uterine cancer	0.000104	0.000884	CcSEcCtD
Vandetanib—Pollakiuria—Epirubicin—uterine cancer	0.000103	0.000883	CcSEcCtD
Vandetanib—Photosensitivity reaction—Epirubicin—uterine cancer	0.000102	0.000872	CcSEcCtD
Vandetanib—Paraesthesia—Etoposide—uterine cancer	0.000102	0.000871	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—uterine cancer	0.000102	0.000867	CcSEcCtD
Vandetanib—Weight decreased—Epirubicin—uterine cancer	0.000101	0.000865	CcSEcCtD
Vandetanib—Dyspnoea—Etoposide—uterine cancer	0.000101	0.000864	CcSEcCtD
Vandetanib—Hyperglycaemia—Epirubicin—uterine cancer	0.000101	0.000862	CcSEcCtD
Vandetanib—Pneumonia—Epirubicin—uterine cancer	0.0001	0.000857	CcSEcCtD
Vandetanib—Infestation—Epirubicin—uterine cancer	9.99e-05	0.000852	CcSEcCtD
Vandetanib—Infestation NOS—Epirubicin—uterine cancer	9.99e-05	0.000852	CcSEcCtD
Vandetanib—Vomiting—Dactinomycin—uterine cancer	9.98e-05	0.000852	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—uterine cancer	9.97e-05	0.00085	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Epirubicin—uterine cancer	9.9e-05	0.000845	CcSEcCtD
Vandetanib—Rash—Dactinomycin—uterine cancer	9.9e-05	0.000845	CcSEcCtD
Vandetanib—Decreased appetite—Etoposide—uterine cancer	9.88e-05	0.000843	CcSEcCtD
Vandetanib—Renal failure—Epirubicin—uterine cancer	9.82e-05	0.000838	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Etoposide—uterine cancer	9.81e-05	0.000837	CcSEcCtD
Vandetanib—Fatigue—Etoposide—uterine cancer	9.8e-05	0.000836	CcSEcCtD
Vandetanib—ABCC1—lymph node—uterine cancer	9.74e-05	0.000881	CbGeAlD
Vandetanib—Stomatitis—Epirubicin—uterine cancer	9.74e-05	0.000831	CcSEcCtD
Vandetanib—Pain—Etoposide—uterine cancer	9.72e-05	0.000829	CcSEcCtD
Vandetanib—Constipation—Etoposide—uterine cancer	9.72e-05	0.000829	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—uterine cancer	9.71e-05	0.000828	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—uterine cancer	9.71e-05	0.000828	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—uterine cancer	9.69e-05	0.000827	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—uterine cancer	9.69e-05	0.000827	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—uterine cancer	9.63e-05	0.000822	CcSEcCtD
Vandetanib—CYP3A4—female reproductive system—uterine cancer	9.61e-05	0.000869	CbGeAlD
Vandetanib—Pollakiuria—Doxorubicin—uterine cancer	9.58e-05	0.000817	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—uterine cancer	9.52e-05	0.000812	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—uterine cancer	9.46e-05	0.000807	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—uterine cancer	9.45e-05	0.000806	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—uterine cancer	9.42e-05	0.000804	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—uterine cancer	9.38e-05	0.0008	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—uterine cancer	9.37e-05	0.000799	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—uterine cancer	9.35e-05	0.000798	CcSEcCtD
Vandetanib—Nausea—Dactinomycin—uterine cancer	9.33e-05	0.000796	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—uterine cancer	9.3e-05	0.000793	CcSEcCtD
Vandetanib—Gastrointestinal pain—Etoposide—uterine cancer	9.29e-05	0.000793	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—uterine cancer	9.24e-05	0.000788	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—uterine cancer	9.24e-05	0.000788	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	9.16e-05	0.000782	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—uterine cancer	9.13e-05	0.000779	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—uterine cancer	9.08e-05	0.000775	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—uterine cancer	9.01e-05	0.000769	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—uterine cancer	9.01e-05	0.000769	CcSEcCtD
Vandetanib—Abdominal pain—Etoposide—uterine cancer	8.98e-05	0.000766	CcSEcCtD
Vandetanib—Body temperature increased—Etoposide—uterine cancer	8.98e-05	0.000766	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—uterine cancer	8.98e-05	0.000766	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—uterine cancer	8.98e-05	0.000766	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—uterine cancer	8.97e-05	0.000765	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—uterine cancer	8.85e-05	0.000755	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—uterine cancer	8.81e-05	0.000752	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—uterine cancer	8.79e-05	0.00075	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—uterine cancer	8.74e-05	0.000746	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—uterine cancer	8.72e-05	0.000744	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—uterine cancer	8.67e-05	0.00074	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—uterine cancer	8.64e-05	0.000737	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—uterine cancer	8.48e-05	0.000723	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—uterine cancer	8.45e-05	0.000721	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—uterine cancer	8.38e-05	0.000715	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—uterine cancer	8.34e-05	0.000711	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—uterine cancer	8.32e-05	0.00071	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—uterine cancer	8.3e-05	0.000708	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—uterine cancer	8.19e-05	0.000699	CcSEcCtD
Vandetanib—Asthenia—Etoposide—uterine cancer	8.15e-05	0.000696	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—uterine cancer	8.14e-05	0.000694	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—uterine cancer	8.13e-05	0.000694	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—uterine cancer	8.08e-05	0.000689	CcSEcCtD
Vandetanib—ABCG2—lymph node—uterine cancer	8.07e-05	0.000729	CbGeAlD
Vandetanib—Pruritus—Etoposide—uterine cancer	8.04e-05	0.000686	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—uterine cancer	8.01e-05	0.000683	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—uterine cancer	8e-05	0.000682	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—uterine cancer	7.92e-05	0.000676	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—uterine cancer	7.86e-05	0.00067	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—uterine cancer	7.84e-05	0.000669	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—uterine cancer	7.81e-05	0.000666	CcSEcCtD
Vandetanib—Diarrhoea—Etoposide—uterine cancer	7.78e-05	0.000663	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—uterine cancer	7.75e-05	0.000661	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—uterine cancer	7.7e-05	0.000657	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—uterine cancer	7.64e-05	0.000652	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—uterine cancer	7.53e-05	0.000642	CcSEcCtD
Vandetanib—Dizziness—Etoposide—uterine cancer	7.52e-05	0.000641	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—uterine cancer	7.5e-05	0.00064	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—uterine cancer	7.48e-05	0.000638	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—uterine cancer	7.41e-05	0.000632	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—uterine cancer	7.36e-05	0.000628	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—uterine cancer	7.33e-05	0.000625	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—uterine cancer	7.27e-05	0.00062	CcSEcCtD
Vandetanib—Vomiting—Etoposide—uterine cancer	7.23e-05	0.000616	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—uterine cancer	7.22e-05	0.000616	CcSEcCtD
Vandetanib—Rash—Etoposide—uterine cancer	7.17e-05	0.000611	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—uterine cancer	7.16e-05	0.000611	CcSEcCtD
Vandetanib—Headache—Etoposide—uterine cancer	7.12e-05	0.000607	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—uterine cancer	7.07e-05	0.000603	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—uterine cancer	6.94e-05	0.000592	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—uterine cancer	6.86e-05	0.000585	CcSEcCtD
Vandetanib—Cough—Epirubicin—uterine cancer	6.81e-05	0.000581	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—uterine cancer	6.81e-05	0.000581	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—uterine cancer	6.76e-05	0.000577	CcSEcCtD
Vandetanib—Nausea—Etoposide—uterine cancer	6.75e-05	0.000576	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—uterine cancer	6.74e-05	0.000575	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—uterine cancer	6.65e-05	0.000567	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—uterine cancer	6.65e-05	0.000567	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—uterine cancer	6.62e-05	0.000565	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	6.6e-05	0.000563	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—uterine cancer	6.5e-05	0.000554	CcSEcCtD
Vandetanib—Oedema—Epirubicin—uterine cancer	6.37e-05	0.000543	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—uterine cancer	6.35e-05	0.000542	CcSEcCtD
Vandetanib—Infection—Epirubicin—uterine cancer	6.33e-05	0.00054	CcSEcCtD
Vandetanib—Cough—Doxorubicin—uterine cancer	6.3e-05	0.000538	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—uterine cancer	6.26e-05	0.000534	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—uterine cancer	6.25e-05	0.000533	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—uterine cancer	6.24e-05	0.000532	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—uterine cancer	6.24e-05	0.000532	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—uterine cancer	6.19e-05	0.000528	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—uterine cancer	6.15e-05	0.000525	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—uterine cancer	6.15e-05	0.000525	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—uterine cancer	6.13e-05	0.000523	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	6.11e-05	0.000521	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—uterine cancer	6.01e-05	0.000513	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—uterine cancer	5.89e-05	0.000503	CcSEcCtD
Vandetanib—Infection—Doxorubicin—uterine cancer	5.86e-05	0.0005	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.8e-05	0.000495	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—uterine cancer	5.78e-05	0.000493	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—uterine cancer	5.77e-05	0.000492	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—uterine cancer	5.76e-05	0.000492	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—uterine cancer	5.73e-05	0.000488	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—uterine cancer	5.72e-05	0.000488	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—uterine cancer	5.68e-05	0.000485	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—uterine cancer	5.61e-05	0.000478	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—uterine cancer	5.54e-05	0.000472	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—uterine cancer	5.5e-05	0.000469	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—uterine cancer	5.49e-05	0.000469	CcSEcCtD
Vandetanib—Constipation—Epirubicin—uterine cancer	5.45e-05	0.000465	CcSEcCtD
Vandetanib—Pain—Epirubicin—uterine cancer	5.45e-05	0.000465	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.37e-05	0.000458	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—uterine cancer	5.33e-05	0.000455	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—uterine cancer	5.29e-05	0.000452	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—uterine cancer	5.25e-05	0.000448	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—uterine cancer	5.21e-05	0.000444	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—uterine cancer	5.19e-05	0.000443	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—uterine cancer	5.12e-05	0.000437	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—uterine cancer	5.09e-05	0.000434	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—uterine cancer	5.08e-05	0.000434	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—uterine cancer	5.04e-05	0.00043	CcSEcCtD
Vandetanib—Pain—Doxorubicin—uterine cancer	5.04e-05	0.00043	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—uterine cancer	5.04e-05	0.00043	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—uterine cancer	5.04e-05	0.00043	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—uterine cancer	4.82e-05	0.000411	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—uterine cancer	4.66e-05	0.000398	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—uterine cancer	4.66e-05	0.000398	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—uterine cancer	4.57e-05	0.00039	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—uterine cancer	4.51e-05	0.000385	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—uterine cancer	4.36e-05	0.000372	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—uterine cancer	4.23e-05	0.000361	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—uterine cancer	4.21e-05	0.000359	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—uterine cancer	4.17e-05	0.000356	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—uterine cancer	4.05e-05	0.000346	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—uterine cancer	4.03e-05	0.000344	CcSEcCtD
Vandetanib—Rash—Epirubicin—uterine cancer	4.02e-05	0.000343	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—uterine cancer	4.01e-05	0.000342	CcSEcCtD
Vandetanib—Headache—Epirubicin—uterine cancer	3.99e-05	0.00034	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—uterine cancer	3.9e-05	0.000333	CcSEcCtD
Vandetanib—Nausea—Epirubicin—uterine cancer	3.78e-05	0.000323	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—uterine cancer	3.75e-05	0.00032	CcSEcCtD
Vandetanib—Rash—Doxorubicin—uterine cancer	3.72e-05	0.000317	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—uterine cancer	3.71e-05	0.000317	CcSEcCtD
Vandetanib—Headache—Doxorubicin—uterine cancer	3.69e-05	0.000315	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—uterine cancer	3.5e-05	0.000299	CcSEcCtD
Vandetanib—ALB—Hemostasis—VEGFA—uterine cancer	3.03e-06	2.12e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—PIK3CA—uterine cancer	3.03e-06	2.12e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—AKT1—uterine cancer	3.02e-06	2.12e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NRAS—uterine cancer	3.02e-06	2.12e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CTNNB1—uterine cancer	3.02e-06	2.12e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NRAS—uterine cancer	2.99e-06	2.1e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTEN—uterine cancer	2.99e-06	2.1e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—NRAS—uterine cancer	2.98e-06	2.09e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EP300—uterine cancer	2.97e-06	2.08e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CDKN1B—uterine cancer	2.95e-06	2.07e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—PTEN—uterine cancer	2.94e-06	2.06e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.93e-06	2.05e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HRAS—uterine cancer	2.92e-06	2.05e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—uterine cancer	2.92e-06	2.05e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—uterine cancer	2.92e-06	2.05e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.91e-06	2.04e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—EP300—uterine cancer	2.91e-06	2.04e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—uterine cancer	2.91e-06	2.04e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—NRAS—uterine cancer	2.91e-06	2.04e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—uterine cancer	2.9e-06	2.03e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CTNNB1—uterine cancer	2.89e-06	2.03e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—NRAS—uterine cancer	2.87e-06	2.01e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—uterine cancer	2.86e-06	2.01e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EP300—uterine cancer	2.85e-06	2e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—PIK3CA—uterine cancer	2.84e-06	1.99e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CDKN1B—uterine cancer	2.83e-06	1.98e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KRAS—uterine cancer	2.82e-06	1.98e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—ERBB2—uterine cancer	2.82e-06	1.98e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTEN—uterine cancer	2.82e-06	1.98e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KRAS—uterine cancer	2.81e-06	1.97e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—uterine cancer	2.81e-06	1.97e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EP300—uterine cancer	2.8e-06	1.97e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HRAS—uterine cancer	2.8e-06	1.96e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—uterine cancer	2.79e-06	1.96e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CTNNB1—uterine cancer	2.79e-06	1.95e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ERBB2—uterine cancer	2.78e-06	1.95e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—NRAS—uterine cancer	2.77e-06	1.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL2—uterine cancer	2.77e-06	1.95e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—uterine cancer	2.77e-06	1.94e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—KRAS—uterine cancer	2.75e-06	1.93e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KRAS—uterine cancer	2.75e-06	1.93e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—uterine cancer	2.74e-06	1.92e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KRAS—uterine cancer	2.74e-06	1.92e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NRAS—uterine cancer	2.72e-06	1.91e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KRAS—uterine cancer	2.72e-06	1.91e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ERBB2—uterine cancer	2.72e-06	1.91e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTEN—uterine cancer	2.71e-06	1.9e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—KRAS—uterine cancer	2.71e-06	1.9e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ESR1—uterine cancer	2.69e-06	1.89e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—EP300—uterine cancer	2.69e-06	1.88e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ERBB2—uterine cancer	2.68e-06	1.88e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL2—uterine cancer	2.67e-06	1.88e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CTNNB1—uterine cancer	2.67e-06	1.87e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NRAS—uterine cancer	2.67e-06	1.87e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL8—uterine cancer	2.63e-06	1.85e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HRAS—uterine cancer	2.62e-06	1.84e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NRAS—uterine cancer	2.62e-06	1.84e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CDKN1B—uterine cancer	2.61e-06	1.83e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—RRM2—uterine cancer	2.61e-06	1.83e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—PTEN—uterine cancer	2.6e-06	1.83e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KRAS—uterine cancer	2.6e-06	1.82e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PIK3CA—uterine cancer	2.59e-06	1.82e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EP300—uterine cancer	2.59e-06	1.82e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—PIK3CA—uterine cancer	2.58e-06	1.81e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL8—uterine cancer	2.58e-06	1.81e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—uterine cancer	2.58e-06	1.81e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—KRAS—uterine cancer	2.57e-06	1.81e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CDKN1B—uterine cancer	2.57e-06	1.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—KRAS—uterine cancer	2.56e-06	1.8e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL8—uterine cancer	2.54e-06	1.78e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—DCN—uterine cancer	2.53e-06	1.78e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—PIK3CA—uterine cancer	2.53e-06	1.77e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PIK3CA—uterine cancer	2.53e-06	1.77e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PIK3CA—uterine cancer	2.52e-06	1.77e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1B—uterine cancer	2.52e-06	1.77e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NRAS—uterine cancer	2.51e-06	1.76e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—uterine cancer	2.51e-06	1.76e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—KRAS—uterine cancer	2.5e-06	1.76e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTEN—uterine cancer	2.5e-06	1.76e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PIK3CA—uterine cancer	2.5e-06	1.75e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—PIK3CA—uterine cancer	2.49e-06	1.75e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EP300—uterine cancer	2.48e-06	1.74e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1B—uterine cancer	2.48e-06	1.74e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—uterine cancer	2.47e-06	1.73e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KRAS—uterine cancer	2.47e-06	1.73e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CTNNB1—uterine cancer	2.47e-06	1.73e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—uterine cancer	2.44e-06	1.71e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—uterine cancer	2.44e-06	1.71e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CTNNB1—uterine cancer	2.43e-06	1.7e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NRAS—uterine cancer	2.42e-06	1.7e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—uterine cancer	2.42e-06	1.7e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTEN—uterine cancer	2.4e-06	1.69e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—uterine cancer	2.4e-06	1.68e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—uterine cancer	2.39e-06	1.68e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—uterine cancer	2.39e-06	1.68e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—EP300—uterine cancer	2.39e-06	1.67e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—uterine cancer	2.39e-06	1.67e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.39e-06	1.67e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CTNNB1—uterine cancer	2.38e-06	1.67e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTEN—uterine cancer	2.37e-06	1.66e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL2—uterine cancer	2.37e-06	1.66e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—uterine cancer	2.36e-06	1.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—uterine cancer	2.36e-06	1.65e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—uterine cancer	2.34e-06	1.64e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CTNNB1—uterine cancer	2.34e-06	1.64e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—uterine cancer	2.34e-06	1.64e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—uterine cancer	2.34e-06	1.64e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—uterine cancer	2.33e-06	1.63e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—uterine cancer	2.32e-06	1.63e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—uterine cancer	2.32e-06	1.63e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—uterine cancer	2.32e-06	1.62e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—uterine cancer	2.31e-06	1.62e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—uterine cancer	2.31e-06	1.62e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—uterine cancer	2.3e-06	1.62e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—uterine cancer	2.3e-06	1.61e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—uterine cancer	2.29e-06	1.61e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EP300—uterine cancer	2.29e-06	1.61e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—uterine cancer	2.29e-06	1.6e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—uterine cancer	2.28e-06	1.6e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—uterine cancer	2.27e-06	1.59e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EP300—uterine cancer	2.26e-06	1.58e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—uterine cancer	2.26e-06	1.58e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.25e-06	1.58e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—uterine cancer	2.23e-06	1.56e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EP300—uterine cancer	2.21e-06	1.55e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—uterine cancer	2.21e-06	1.55e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—uterine cancer	2.2e-06	1.54e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—uterine cancer	2.2e-06	1.54e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—uterine cancer	2.19e-06	1.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—uterine cancer	2.19e-06	1.54e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—uterine cancer	2.19e-06	1.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—uterine cancer	2.18e-06	1.53e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EP300—uterine cancer	2.18e-06	1.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—uterine cancer	2.16e-06	1.52e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.15e-06	1.51e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—uterine cancer	2.15e-06	1.51e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—uterine cancer	2.14e-06	1.5e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1B—uterine cancer	2.14e-06	1.5e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—uterine cancer	2.14e-06	1.5e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—uterine cancer	2.13e-06	1.49e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—uterine cancer	2.12e-06	1.49e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—uterine cancer	2.12e-06	1.49e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—uterine cancer	2.11e-06	1.48e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—uterine cancer	2.11e-06	1.48e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—uterine cancer	2.11e-06	1.48e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—uterine cancer	2.11e-06	1.48e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—uterine cancer	2.1e-06	1.47e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—EP300—uterine cancer	2.1e-06	1.47e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—uterine cancer	2.09e-06	1.47e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—uterine cancer	2.08e-06	1.46e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—uterine cancer	2.07e-06	1.45e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—uterine cancer	2.07e-06	1.45e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—uterine cancer	2.07e-06	1.45e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—uterine cancer	2.06e-06	1.45e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1B—uterine cancer	2.06e-06	1.45e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—uterine cancer	2.06e-06	1.45e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—uterine cancer	2.06e-06	1.44e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—uterine cancer	2.04e-06	1.43e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—uterine cancer	2.04e-06	1.43e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—uterine cancer	2.04e-06	1.43e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—uterine cancer	2.03e-06	1.42e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—uterine cancer	2.02e-06	1.42e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—uterine cancer	2e-06	1.4e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—uterine cancer	1.99e-06	1.4e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—uterine cancer	1.99e-06	1.39e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—uterine cancer	1.97e-06	1.38e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—uterine cancer	1.97e-06	1.38e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—uterine cancer	1.95e-06	1.37e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—uterine cancer	1.95e-06	1.37e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—uterine cancer	1.95e-06	1.37e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—uterine cancer	1.93e-06	1.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—uterine cancer	1.92e-06	1.35e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—uterine cancer	1.92e-06	1.35e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—uterine cancer	1.92e-06	1.34e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—uterine cancer	1.9e-06	1.33e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EP300—uterine cancer	1.88e-06	1.32e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—uterine cancer	1.88e-06	1.32e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—uterine cancer	1.87e-06	1.31e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—uterine cancer	1.86e-06	1.3e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—uterine cancer	1.85e-06	1.29e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—uterine cancer	1.84e-06	1.29e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—uterine cancer	1.84e-06	1.29e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1B—uterine cancer	1.83e-06	1.28e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—uterine cancer	1.82e-06	1.28e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EP300—uterine cancer	1.81e-06	1.27e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—uterine cancer	1.79e-06	1.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—uterine cancer	1.78e-06	1.25e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—uterine cancer	1.78e-06	1.25e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—uterine cancer	1.77e-06	1.24e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—uterine cancer	1.77e-06	1.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—uterine cancer	1.76e-06	1.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—uterine cancer	1.76e-06	1.23e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—STK11—uterine cancer	1.75e-06	1.23e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.75e-06	1.23e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—uterine cancer	1.75e-06	1.23e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—uterine cancer	1.73e-06	1.21e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—uterine cancer	1.72e-06	1.21e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—uterine cancer	1.72e-06	1.2e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—uterine cancer	1.7e-06	1.19e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—uterine cancer	1.7e-06	1.19e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—uterine cancer	1.7e-06	1.19e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—uterine cancer	1.69e-06	1.19e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—uterine cancer	1.68e-06	1.18e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—uterine cancer	1.67e-06	1.17e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—uterine cancer	1.64e-06	1.15e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—uterine cancer	1.62e-06	1.14e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—uterine cancer	1.62e-06	1.13e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—uterine cancer	1.61e-06	1.13e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EP300—uterine cancer	1.6e-06	1.13e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—uterine cancer	1.58e-06	1.11e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—uterine cancer	1.57e-06	1.1e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—uterine cancer	1.56e-06	1.1e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—uterine cancer	1.56e-06	1.09e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—uterine cancer	1.55e-06	1.09e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—uterine cancer	1.55e-06	1.08e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—uterine cancer	1.52e-06	1.07e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—uterine cancer	1.51e-06	1.06e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—uterine cancer	1.51e-06	1.06e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—uterine cancer	1.5e-06	1.05e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—uterine cancer	1.5e-06	1.05e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—uterine cancer	1.49e-06	1.05e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—uterine cancer	1.46e-06	1.02e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—uterine cancer	1.44e-06	1.01e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—uterine cancer	1.39e-06	9.76e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—uterine cancer	1.38e-06	9.71e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—uterine cancer	1.37e-06	9.57e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—uterine cancer	1.36e-06	9.53e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—uterine cancer	1.35e-06	9.44e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—uterine cancer	1.34e-06	9.41e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—uterine cancer	1.34e-06	9.37e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—uterine cancer	1.32e-06	9.25e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—uterine cancer	1.32e-06	9.23e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—uterine cancer	1.3e-06	9.1e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—EP300—uterine cancer	1.3e-06	9.09e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—uterine cancer	1.29e-06	9.06e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—uterine cancer	1.29e-06	9.03e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—uterine cancer	1.27e-06	8.9e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—uterine cancer	1.24e-06	8.7e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—uterine cancer	1.19e-06	8.33e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—uterine cancer	1.15e-06	8.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—uterine cancer	1.14e-06	7.97e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—uterine cancer	1.1e-06	7.7e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—uterine cancer	1.1e-06	7.68e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—uterine cancer	9.7e-07	6.8e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—uterine cancer	9.59e-07	6.72e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—uterine cancer	7.83e-07	5.49e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—uterine cancer	7.34e-07	5.15e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—EP300—uterine cancer	7e-07	4.91e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—uterine cancer	5.18e-07	3.63e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—uterine cancer	4.23e-07	2.97e-06	CbGpPWpGaD
